127 related articles for article (PubMed ID: 32853479)
1. Report of a germline double heterozygote in MSH2 and PALB2.
Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Patsea E; Lypas G; Nasioulas G
Mol Genet Genomic Med; 2020 Oct; 8(10):e1242. PubMed ID: 32853479
[TBL] [Abstract][Full Text] [Related]
2. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.
Fewings E; Larionov A; Redman J; Goldgraben MA; Scarth J; Richardson S; Brewer C; Davidson R; Ellis I; Evans DG; Halliday D; Izatt L; Marks P; McConnell V; Verbist L; Mayes R; Clark GR; Hadfield J; Chin SF; Teixeira MR; Giger OT; Hardwick R; di Pietro M; O'Donovan M; Pharoah P; Caldas C; Fitzgerald RC; Tischkowitz M
Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):489-498. PubMed ID: 29706558
[TBL] [Abstract][Full Text] [Related]
3. Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients.
Wu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xu Y; Xie Y
Breast Cancer Res Treat; 2020 Feb; 179(3):605-614. PubMed ID: 31768816
[TBL] [Abstract][Full Text] [Related]
4. Characterization of a novel germline PALB2 duplication in a hereditary breast and ovarian cancer family.
Yang C; Arnold AG; Trottier M; Sonoda Y; Abu-Rustum NR; Zivanovic O; Robson ME; Stadler ZK; Walsh MF; Hyman DM; Offit K; Zhang L
Breast Cancer Res Treat; 2016 Dec; 160(3):447-456. PubMed ID: 27757719
[TBL] [Abstract][Full Text] [Related]
5. Clinical Validity of Next-Generation Sequencing Multi-Gene Panel Testing for Detecting Pathogenic Variants in Patients With Hereditary Breast-Ovarian Cancer Syndrome.
Yoo J; Lee GD; Kim JH; Lee SN; Chae H; Han E; Kim Y; Kim M
Ann Lab Med; 2020 Mar; 40(2):148-154. PubMed ID: 31650731
[TBL] [Abstract][Full Text] [Related]
6. Identification and Characterization of an Exonic Duplication in
Bouras A; Lafaye C; Leone M; Kherraf ZE; Martin-Denavit T; Fert-Ferrer S; Calender A; Boutry-Kryza N
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054852
[No Abstract] [Full Text] [Related]
7. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
Alter BP; Best AF
Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
[TBL] [Abstract][Full Text] [Related]
8. PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk.
Vagena A; Papamentzelopoulou M; Kalfakakou D; Kollia P; Papadimitriou C; Psyrri A; Apostolou P; Fountzilas G; Konstantopoulou I; Yannoukakos D; Fostira F
J Hum Genet; 2019 Aug; 64(8):767-773. PubMed ID: 31089269
[TBL] [Abstract][Full Text] [Related]
9. Germline mutations of PALB2 gene in a sequential series of Chinese patients with breast cancer.
Zhang K; Zhou J; Zhu X; Luo M; Xu C; Yu J; Deng M; Zheng S; Chen Y
Breast Cancer Res Treat; 2017 Dec; 166(3):865-873. PubMed ID: 28825143
[TBL] [Abstract][Full Text] [Related]
10. Cancer Risks Associated With Germline
Yang X; Leslie G; Doroszuk A; Schneider S; Allen J; Decker B; Dunning AM; Redman J; Scarth J; Plaskocinska I; Luccarini C; Shah M; Pooley K; Dorling L; Lee A; Adank MA; Adlard J; Aittomäki K; Andrulis IL; Ang P; Barwell J; Bernstein JL; Bobolis K; Borg Å; Blomqvist C; Claes KBM; Concannon P; Cuggia A; Culver JO; Damiola F; de Pauw A; Diez O; Dolinsky JS; Domchek SM; Engel C; Evans DG; Fostira F; Garber J; Golmard L; Goode EL; Gruber SB; Hahnen E; Hake C; Heikkinen T; Hurley JE; Janavicius R; Kleibl Z; Kleiblova P; Konstantopoulou I; Kvist A; Laduca H; Lee ASG; Lesueur F; Maher ER; Mannermaa A; Manoukian S; McFarland R; McKinnon W; Meindl A; Metcalfe K; Mohd Taib NA; Moilanen J; Nathanson KL; Neuhausen S; Ng PS; Nguyen-Dumont T; Nielsen SM; Obermair F; Offit K; Olopade OI; Ottini L; Penkert J; Pylkäs K; Radice P; Ramus SJ; Rudaitis V; Side L; Silva-Smith R; Silvestri V; Skytte AB; Slavin T; Soukupova J; Tondini C; Trainer AH; Unzeitig G; Usha L; van Overeem Hansen T; Whitworth J; Wood M; Yip CH; Yoon SY; Yussuf A; Zogopoulos G; Goldgar D; Hopper JL; Chenevix-Trench G; Pharoah P; George SHL; Balmaña J; Houdayer C; James P; El-Haffaf Z; Ehrencrona H; Janatova M; Peterlongo P; Nevanlinna H; Schmutzler R; Teo SH; Robson M; Pal T; Couch F; Weitzel JN; Elliott A; Southey M; Winqvist R; Easton DF; Foulkes WD; Antoniou AC; Tischkowitz M
J Clin Oncol; 2020 Mar; 38(7):674-685. PubMed ID: 31841383
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and spectrum of germline rare variants in BRCA1/2 and PALB2 among breast cancer cases in Sarawak, Malaysia.
Yang XR; Devi BCR; Sung H; Guida J; Mucaki EJ; Xiao Y; Best A; Garland L; Xie Y; Hu N; Rodriguez-Herrera M; Wang C; Jones K; Luo W; Hicks B; Tang TS; Moitra K; Rogan PK; Dean M
Breast Cancer Res Treat; 2017 Oct; 165(3):687-697. PubMed ID: 28664506
[TBL] [Abstract][Full Text] [Related]
12. Germline mutations in Chinese ovarian cancer with or without breast cancer.
Kwong A; Ho CYS; Shin VY; Au CH; Luk WP; Fung LH; Chan TL; Chan KKL; Ngan HYS; Ma ESK
Mol Genet Genomic Med; 2022 Jul; 10(7):e1940. PubMed ID: 35608067
[TBL] [Abstract][Full Text] [Related]
13. [The first molecular analysis of a Hungarian HNPCC family: a novel MSH2 germline mutation].
Czakó L; Tiszlavicz L; Takács R; Baradnay G; Lonovics J; Cserni G; Závodná K; Bartosova Z
Orv Hetil; 2005 May; 146(20):1009-16. PubMed ID: 15945244
[TBL] [Abstract][Full Text] [Related]
14. A germline
Zhong Y; Schubert J; Wu J; Xu F; Lin F; Cao K; Zelley K; Luo M; Foster JB; Cole KA; MacFarland SP; Resnick AC; Storm PB; Li MM
Cold Spring Harb Mol Case Stud; 2020 Aug; 6(4):. PubMed ID: 32554798
[No Abstract] [Full Text] [Related]
15. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
[TBL] [Abstract][Full Text] [Related]
16. A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer.
Velázquez C; Esteban-Cardeñosa EM; Lastra E; Abella LE; de la Cruz V; Lobatón CD; Durán M; Infante M
Breast; 2019 Feb; 43():91-96. PubMed ID: 30521987
[TBL] [Abstract][Full Text] [Related]
17. Impact of gene-specific germline pathogenic variants on presentation of endometrial cancer in Lynch syndrome.
Bogani G; Ricci MT; Vitellaro M; Ditto A; Chiappa V; Raspagliesi F
Int J Gynecol Cancer; 2019 May; 29(4):705-710. PubMed ID: 30772826
[TBL] [Abstract][Full Text] [Related]
18. Spectrum of PALB2 germline mutations and characteristics of PALB2-related breast cancer: Screening of 16,501 unselected patients with breast cancer and 5890 controls by next-generation sequencing.
Zhou J; Wang H; Fu F; Li Z; Feng Q; Wu W; Liu Y; Wang C; Chen Y
Cancer; 2020 Jul; 126(14):3202-3208. PubMed ID: 32339256
[TBL] [Abstract][Full Text] [Related]
19. Cancer risk management among female BRCA1/2, PALB2, CHEK2, and ATM carriers.
Cragun D; Weidner A; Tezak A; Clouse K; Pal T
Breast Cancer Res Treat; 2020 Jul; 182(2):421-428. PubMed ID: 32445176
[TBL] [Abstract][Full Text] [Related]
20. [The French Genetic and Cancer Consortium guidelines for multigene panel analysis in hereditary breast and ovarian cancer predisposition].
Moretta J; Berthet P; Bonadona V; Caron O; Cohen-Haguenauer O; Colas C; Corsini C; Cusin V; De Pauw A; Delnatte C; Dussart S; Jamain C; Longy M; Luporsi E; Maugard C; Nguyen TD; Pujol P; Vaur D; Andrieu N; Lasset C; Noguès C;
Bull Cancer; 2018 Oct; 105(10):907-917. PubMed ID: 30268633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
